Email Updates

Search form

You are here

Webinar: CDC and WHO Review Current PrEP Guidelines

April 4, 2017

Hundreds of people tuned in to hear researchers discuss the available data on “time to protection” required for effective oral PrEP with TDF/FTC—i.e., how many doses must be taken to build up protective levels of the drug in the blood? The answer is—it varies. Not surprisingly then, so do the guidelines for PrEP use.

As webinar participants learned, the data are varied and subject to interpretation. The World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC) recommend different time frames to reach protection in their respective guidelines for oral PrEP use. Both of these recommendations are based on measurements of the amount of drug that accumulates in blood and/or tissue over a specific period of time. The studies of how drugs are taken into the body and how they leave the body is called “pharmacokinetics” and “pharmacodynamics” or “PK” and “PD” for short, as explained in our primer for advocates. There isn’t a single PK measurement that is associated with PrEP protection—so both WHO and CDC guidelines are based on inference.

AVAC hosted a follow-on webinar presentation where representatives from both the CDC and WHO reviewed their respective guidance development processes and the role, use, contexts and audience for guidance documents.

Watch the recording on YouTube, listen to an mp3 version or download the slides. Q&A starts approximately 55 minutes in.